Sodium Iodide I 131
"The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).
Medullary thyroid cancer develops in cells in the thyroid gland that m"...
Sodium Iodide I 131
DOSAGE AND ADMINISTRATION
The suggested oral dosage ranges employed in the average patient (70 kg) for diagnostic procedures for thyroid function are as follows:
Thyroid Uptake: 0.185 to 0.555 megabecquerels (5 to 15 microcuries)
Scintiscanning:1.85 to 3.7 megabecquerels (50 to 100 microcuries)
Localization of extra-thyroidal metastases: 37 megabecquerels (1000 microcuries).
Waterproof gloves should be used during the entire handling and administration procedure.
The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.
The estimated absorbed radiation doses2 to an average (70 kg) euthyroid (normal functioning thyroid) patient from an oral dose of 3.7 megabecquerels (100 microcuries) of iodine I-131 are shown in Table 4.
Table 4. Absorbed Radiation Doses
|Tissue||Absorbed radiation doses for 3.7 megabecquerels (100 Microcuries)|
2MIRD DOSE ESTIMATE REPORT No. 5. Summary of Current Radiation Dose Estimates to Humans from 123I, 124I, 125I, 126I, 130I, 131I, and 132I Sodium Iodide. J. Nucl. Med., 16, No. 9, 857-60 (1975).
Catalog Number 300.
Sodium Iodide I 131 (sodium iodide i 131 (sodium iodide i 131 capsules) capsules) Diagnostic Capsules are supplied in a strength of 3.7 megabecquerels (100 microcuries) at time of calibration.
The capsules are packaged in plastic vials containing 5, 10, or 15 capsules per vial.
Storage And Handling
Sodium Iodide I 131 (sodium iodide i 131 (sodium iodide i 131 capsules) capsules) Diagnostic capsules should be stored at controlled room temperature 20-25°C (68-77°F) [See USP].
Storage and disposal of Sodium Iodide I 131 (sodium iodide i 131 (sodium iodide i 131 capsules) capsules) Diagnostic Capsules should be controlled in a manner that is in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.
The U.S. Nuclear Regulatory Commission has approved distribution of this radiopharmaceutical to persons licensed to use byproduct material listed in Section 35.100, and to persons who hold an equivalent license by an Agreement State.
Revised 1/2003. Mallinckrodt Inc., St. Louis, MO 63134.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/19/2009
Additional Sodium Iodide I 131 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.